Abstract
The prion protein (PrP) is currently one of the most studied molecules in the neurosciences. It is the main cause of a group of neurological diseases collectively called transmissible spongiform encephalopathies that severely affect both humans and a variety of mammals. Much effort has been directed to understanding the molecular basis of PrP activity, both in physiological and pathological terms. In this context, identification of neuronally-relevant interactors of PrP may play a crucial role. We recently discovered a specific, high-affinity (nanomolar KD) interaction with tyrosine hydroxylase (TH), a enzyme catalyzing the rate-limiting step in the synthesis of the neurotransmitter dopamine. Using molecular biological, biochemical and biophysical techniques we identified the C-terminal structured domain of PrP and the Nterminal regulatory domain of TH as interacting domains between these two proteins. This interaction does not affect TH activity in vitro, although co-expression experiments in HeLa and Chinese hamster ovary cells revealed that PrP is able to internalize TH. Moreover, TH modulated the level of expression of PrP and its localization at the plasma membrane. This novel interaction between two proteins of central importance in nervous system function may shed new light on our understanding of PrP in neurological diseases.
Keywords: Prion, tyrosine hydroxylase, protein-protein interaction, surface plasmon resonance.
CNS & Neurological Disorders - Drug Targets
Title:A Novel Prion Protein-Tyrosine Hydroxylase Interaction
Volume: 13 Issue: 5
Author(s): Mattia Vicario, Adriana Zagari, Vincenzo Granata, Francesca Munari, Stefano Mammi, Luigi Bubacco, Stephen D. Skaper and Alessandro Negro
Affiliation:
Keywords: Prion, tyrosine hydroxylase, protein-protein interaction, surface plasmon resonance.
Abstract: The prion protein (PrP) is currently one of the most studied molecules in the neurosciences. It is the main cause of a group of neurological diseases collectively called transmissible spongiform encephalopathies that severely affect both humans and a variety of mammals. Much effort has been directed to understanding the molecular basis of PrP activity, both in physiological and pathological terms. In this context, identification of neuronally-relevant interactors of PrP may play a crucial role. We recently discovered a specific, high-affinity (nanomolar KD) interaction with tyrosine hydroxylase (TH), a enzyme catalyzing the rate-limiting step in the synthesis of the neurotransmitter dopamine. Using molecular biological, biochemical and biophysical techniques we identified the C-terminal structured domain of PrP and the Nterminal regulatory domain of TH as interacting domains between these two proteins. This interaction does not affect TH activity in vitro, although co-expression experiments in HeLa and Chinese hamster ovary cells revealed that PrP is able to internalize TH. Moreover, TH modulated the level of expression of PrP and its localization at the plasma membrane. This novel interaction between two proteins of central importance in nervous system function may shed new light on our understanding of PrP in neurological diseases.
Export Options
About this article
Cite this article as:
Vicario Mattia, Zagari Adriana, Granata Vincenzo, Munari Francesca, Mammi Stefano, Bubacco Luigi, Skaper D. Stephen and Negro Alessandro, A Novel Prion Protein-Tyrosine Hydroxylase Interaction, CNS & Neurological Disorders - Drug Targets 2014; 13 (5) . https://dx.doi.org/10.2174/1871527313666140711092955
DOI https://dx.doi.org/10.2174/1871527313666140711092955 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Rescuing Mutant CFTR: A Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis
Current Pharmaceutical Design Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Harnessing Anesthesia and Brain Imaging for the Study of Human Consciousness
Current Pharmaceutical Design Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures
Current Molecular Pharmacology Phosphorylation-Dephosphorylation Imbalance of Cytoskeletal Associated Proteins in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Neuropharmacology of Implicit Learning
Current Neuropharmacology Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
CNS & Neurological Disorders - Drug Targets The Psychoactive Effects of Aromatic Amino Acids
Current Nutrition & Food Science Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients
Current Rheumatology Reviews The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Raloxifene: Cardiovascular Considerations
Mini-Reviews in Medicinal Chemistry Rational Design and Engineering of a Mutant Variant of Urate Oxidase as a Therapeutic Enzyme: A Molecular Dynamics Simulation Approach
Current Computer-Aided Drug Design The Prediction of Amphiphilic α-Helices
Current Protein & Peptide Science